Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Angiodynamics (ANGO) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Angiodynamics (ANGO) over the last 17 years, with Q4 2025 value amounting to $3.2 million.

  • Angiodynamics' Change in Accured Expenses fell 5748.09% to $3.2 million in Q4 2025 from the same period last year, while for Nov 2025 it was -$15.9 million, marking a year-over-year decrease of 17569.31%. This contributed to the annual value of -$15.9 million for FY2025, which is 15766.95% down from last year.
  • Per Angiodynamics' latest filing, its Change in Accured Expenses stood at $3.2 million for Q4 2025, which was down 5748.09% from -$10.7 million recorded in Q3 2025.
  • In the past 5 years, Angiodynamics' Change in Accured Expenses registered a high of $17.7 million during Q1 2024, and its lowest value of -$16.5 million during Q3 2023.
  • Moreover, its 5-year median value for Change in Accured Expenses was $2.3 million (2021), whereas its average is $945550.0.
  • Per our database at Business Quant, Angiodynamics' Change in Accured Expenses plummeted by 44688.24% in 2022 and then skyrocketed by 51514.3% in 2024.
  • Over the past 5 years, Angiodynamics' Change in Accured Expenses (Quarter) stood at $1.8 million in 2021, then surged by 235.72% to $6.1 million in 2022, then surged by 153.34% to $15.6 million in 2023, then tumbled by 51.97% to $7.5 million in 2024, then tumbled by 57.48% to $3.2 million in 2025.
  • Its last three reported values are $3.2 million in Q4 2025, -$10.7 million for Q3 2025, and $2.6 million during Q2 2025.